Shares of Seres Therapeutics Inc. (MCRB) were up strongly after news of a collaboration deal with AstraZeneca. In the collaboration deal, MCRB will receive $20M as well as financial support for its research activities in microbiome immuno-oncology. Here’s a recap.
Read Article
AcelRx (ACRX) shares slumped in trading today after disappointing earnings results. The company reported $613K in revenue vs. $1.51M consensus estimate. While this was less than half of what was expected, it was not a huge surprise since the company missed revenue estimates by comparable margins over the previous five earnings releases. However, there was […]
Read Article
Here’s a sneak peek of one of the industry’s most reputable, hands-on trading programs with Mike Patton. Grab a free day pass to one of our live signal trading rooms today>>http://bit.ly/fb-free-pass
Read Article
Bio-Path Holdings Inc (BPTH) shares were up dramatically today, and then they fell very, very quickly. The stock’s price rose from under $3 per share back in late February to over $70 per share. While the company did release a report claiming there BP1001 treatment demonstrated “meaningful clinical improvement”, this is a far cry from […]
Read Article
AcelRx Pharmaceuticals (ACRX) shares have been up recently as the company awaits an FDA decision on its product Zalviso. Zalviso has already received approval in the European Union, but the FDA previously requested the company to do an additional trial to address certain concerns. AcelRx successfully completed the additional trial and expects the FDA to […]
Read Article
Evoke Pharma Inc. (EVOK) shares were down dramatically today after the FDA noted concerns about the company’s product Gimoti, which is currently awaiting FDA approval. Although the FDA’s comments are not indicative of its final conclusion, they nevertheless highlight likely areas of contention over granting approval for the drug, and as a result, investors reacted […]
Read Article
Lexicon Pharmaceuticals (LXRX) rallied strongly today after the European Medicines Agency’s Committee for Medicinal Product for Human Use gave LXRX’s Zynquista a positive mention. Zynquista is a joint development between Lexicon and Sanofi. Zynquista’s application for approval in the United States and Europe has been accepted and is currently under review. Here’s a recap.
Read Article
Here’s a sneak peek of one of the industry’s most reputable, hands-on trading programs with Mike Patton. Grab a free day pass to one of our live signal trading rooms today>>http://bit.ly/fb-free-pass
Read Article
Aceto Corporation (ACET) shares are down today after rising yesterday. The company filed for chapter 11 bankruptcy on February 20th, causing the stock to plunge over 65%. The bounce appeared to be merely technical in nature, as trading data overwhelming shows net selling over today’s session. The company plans to make some adjustments in order […]
Read Article
Karyopharm Therapeutics Inc (KPTI) shares were down today as the company awaits the FDA’s decision on its Selinexor new drug application (“NDA”). The company’s stock dropped sharply on Friday, losing around 50% of its value due to FDA notes being leaked, in which the FDA voiced skepticism as to the benefit of approving the new […]
Read Article
We choose to let our members and students speak for themselves. We do not actively solicit testimonials, no compensation has been paid for any testimonial, and testimonials are not necessarily representative of the experience of all students. All monetary claims made in testimonials that you see depicted in our marketing material have been verified by Prosper Trading Academy and attested to by the members that have given them. Verified testimonials encompass “experience” reviews that highlight the personal experiences of working with our team and “performance” testimonials where we verify trading success of students who have enrolled in our programs.Given the broad reach of the internet, testimonials and reviews of our programs that we have not been able to verify can be found on various websites across the internet which are beyond our editorial control. While we do very much enjoy hearing positive things from our students and it is critical to our mission that everyone is satisfied with their journey with Prosper, we encourage you to take both verified and unverified testimonials for what they are.